Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Adamax
A modified Semax analog studied in neuroprotection and cognition research.
- Half-life (approx.)
- ~20–60 min (approx., intranasal)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 5, 10 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Adamax is a modified Semax analog with an extended pharmacokinetic profile studied in Russian nootropic research literature. Investigations focus on BDNF expression, neuroprotection, and cognitive performance in animal models. Modified Semax analog with enhanced stability profile in intranasal neuropharmacology literature.
Structure & identity
Semax-derived heptapeptide analog (N-terminal modifications)
- Sequence / structure
- Semax-derived heptapeptide analog (N-terminal modifications)
Mechanism
Semax-derived analog with enhanced stability; modulates BDNF and NGF expression in CNS models. N-terminal modifications extend exposure relative to parent Semax in rodent PK studies.
Studies & clinical programs
Rat stroke models
Published research models
- Peer-reviewed literature documents endpoints under Rat stroke models experimental designs.
Morris water maze
Published research models
- Peer-reviewed literature documents endpoints under Morris water maze experimental designs.
BDNF expression assays
Published research models
- Peer-reviewed literature documents endpoints under BDNF expression assays experimental designs.
Research models in literature
- Rat stroke models
- Morris water maze
- BDNF expression assays
Literature highlights
- Semax-derived analog with stability modifications explored in stroke and cognitive rodent models.
- BDNF and NGF expression assays used as mechanistic readouts in CNS injury research.
- Compared with parent Semax in intranasal neuroprotection literature.
Combination research notes
Compared with Semax and Semax+Selank blends in nootropic research contexts.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Handling cautions
- Intranasal and injectable forms are not interchangeable
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Refrigerated (2–8 °C), sealed | Research peptide powder for nasal formulations should remain cold and dry until reconstitution; amidate forms may have distinct published stability guidance. |
| Reconstituted (nasal solution) | Sterile water or bacteriostatic water, refrigerated | Nasal research solutions are often prepared at lower concentrations; use within published stability windows (commonly 1–2 weeks refrigerated). |
| Working aliquots | Single-use nasal sprayer fills or frozen micro-aliquots | Avoid contamination of multi-use bottles in lab settings; sterile technique and cold chain reduce protease and microbial risk. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Reconstituted per research protocol; intranasal forms differ from injectable.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance